Home » Posts tagged with » brazikumab
AbbVie acquisition of Allergan gets antitrust clearance from US FTC

AbbVie acquisition of Allergan gets antitrust clearance from US FTC

AbbVie acquisition of Allergan update : US biopharma company AbbVie has secured clearance from the US Federal Trade Commission (FTC) for its previously announced $63 billion acquisition of Botox developer Allergan. According to AbbVie, the approval from the FTC satisfies all the necessary antitrust clearances required for the closing of the cash cum stock deal […]

Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle

Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma acquisition news. Financial details of the two deals have not been disclosed. The divestments are being taken up in an effort to wrap up the $63 billion AbbVie acquisition of […]

Continue reading …